Sucampo Pharmaceuticals Inc. (SCMP) Given Average Recommendation of “Buy” by Brokerages
Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) have earned an average rating of “Buy” from the twelve analysts that are presently covering the company. Five investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $18.11.
SCMP has been the topic of several recent analyst reports. Northland Securities initiated coverage on Sucampo Pharmaceuticals in a report on Wednesday, September 7th. They set an “outperform” rating and a $15.00 price objective on the stock. Mizuho cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price objective on the stock. in a report on Thursday, August 4th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Vetr cut Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price objective on the stock. in a report on Monday, September 19th. Finally, Maxim Group cut their price objective on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, August 1st.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 3.735% during trading on Tuesday, reaching $13.015. The company’s stock had a trading volume of 169,294 shares. The stock’s 50 day moving average price is $12.20 and its 200 day moving average price is $11.52. The company has a market cap of $557.17 million, a PE ratio of 45.667 and a beta of 1.57. Sucampo Pharmaceuticals has a 52 week low of $9.59 and a 52 week high of $21.27.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/sucampo-pharmaceuticals-inc-scmp-given-average-recommendation-of-buy-by-brokerages.html
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.01. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. The business had revenue of $52 million for the quarter, compared to analysts’ expectations of $48.33 million. During the same quarter in the previous year, the business posted $0.21 EPS. Sucampo Pharmaceuticals’s revenue for the quarter was up 49.1% on a year-over-year basis. Equities research analysts predict that Sucampo Pharmaceuticals will post $1.03 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of SCMP. BlackRock Fund Advisors raised its position in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock valued at $17,816,000 after buying an additional 48,420 shares during the period. LSV Asset Management raised its position in Sucampo Pharmaceuticals by 287.9% in the second quarter. LSV Asset Management now owns 482,527 shares of the biopharmaceutical company’s stock valued at $5,293,000 after buying an additional 358,127 shares during the period. Teachers Advisors Inc. raised its position in Sucampo Pharmaceuticals by 12.7% in the second quarter. Teachers Advisors Inc. now owns 477,229 shares of the biopharmaceutical company’s stock valued at $5,235,000 after buying an additional 53,838 shares during the period. Oxford Asset Management raised its position in Sucampo Pharmaceuticals by 27.1% in the second quarter. Oxford Asset Management now owns 409,342 shares of the biopharmaceutical company’s stock valued at $4,490,000 after buying an additional 87,158 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ raised its position in Sucampo Pharmaceuticals by 227.3% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 367,900 shares of the biopharmaceutical company’s stock valued at $4,036,000 after buying an additional 255,500 shares during the period. 40.64% of the stock is currently owned by hedge funds and other institutional investors.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.